Recent Posts
- FDA Okays Blood Test for Ovarian Cancer
- Replication At DNA Damage Sites Highlights Fanconi Anemia And Breast Cancer Proteins
- ASCO To Hold Annual Meeting In Chicago For The Next Ten Years: City Seen As Best Choice To Host Meeting That Continues To Grow
- Protein Partnership Leads To Pediatric Tumor Regression
- ASCO Awarded CEO Cancer Gold Standard: Achievement Underscores Organization’s Commitment To The Health And Well-Being Of Its Employees
Random Posts
- Clues To How Adrenal Cancer Forms
- Taking Aim At Mysterious DNA Structures In The Battle Against Cancer
- RSNA: Ultrasound, MRI Helpful Aids for Dense Breasts
- SABCS: Novel Agents Shine at Conference
- Cancer Patients Benefit From Speed, Accuracy Of RapidArc Radiotherapy Treatments
- Childhood Cancer Cases And Common Household Pesticides Linked In Washington Area
- Robotic Surgery Expert Dr. David B. Samadi Discusses The Benefits Of Surgery For Organ Confined Prostate Cancer
- Women Lag Behind Men in Cancer Trial Representation (CME/CE)
- Agents Targeting Prostate Cancer Bone Metastasis
- Stanford, Palo Alto Medical Foundation Launch Comprehensive Breast Cancer Study
Prescription Cancer Drugs
Cougar Biotechnology Initiates Phase III Trial Of CB7630 (Abiraterone Acetate) In Chemotherapy-Naïve Castration-Resistant Prostate Cancer Patients
Posted by: admin in Cancer Treatment, Prescription Cancer Drugs on May 04th, 2009
Cougar Biotechnology, Inc. (NASDAQ: CGRB) announced the initiation of a Phase III clinical trial (COU-AA-302) of its lead drug candidate CB7630 (abiraterone acetate) in patients with chemotherapy-naïve castration-resistant prostate cancer (CRPC). The COU-AA-302 Phase III trial is a randomized, double-blind, placebo-controlled trial of CB7630 plus prednisone in patients with metastatic CRPC who have not yet received treatment with chemotherapy. The trial is expected to enroll approximately 1,000 patients who will be randomized (1:1) to receive either CB7630 plus prednisone or placebo plus prednisone. The trial will be conducted at approximately 150 sites in North America, Europe and Australia. The co-primary endpoints of the trial are progression free survival and overall survival. The Company plans to use the progression free survival data from the trial as the basis for submission of a New Drug Application and a Marketing Authorization Application for Accelerated and Conditional Approval from the regulatory agencies.
Alan H. Auerbach, Chief Executive Officer and President of Cougar Biotechnology, said, “Initiation of this Phase III trial of CB7630 in chemotherapy-naïve prostate cancer patients represents an important milestone in the clinical development of CB7630. As these patients continue to represent a market that is underserved with current treatments, we are pleased to initiate the COU-AA-302 Phase III trial in this patient population.”
Arturo Molina, M.D., M.S., FACP, Chief Medical Officer and Executive Vice President of Clinical Research and Development of Cougar, added, “The interim results of our Phase II trials of CB7630 have shown strong evidence of antitumor activity in patients with metastatic CRPC who have not yet received chemotherapy; therefore, we are pleased to initiate the COU-AA-302 Phase III trial in this patient population. Due to the high level of awareness of CB7630 in the urology and medical oncology communities, we look forward to aggressively enrolling this Phase III trial.”
Source
Cougar Biotechnology
No Comments »
No comments yet.
RSS feed for comments on this post. TrackBack URL
Leave a comment
You must be logged in to post a comment.